The Foreign Direct Investment (FDI) equity into the pharmaceutical industry has shown significant growth in the first half of 2024-25, following a 48 percent drop in fiscal 2023-24 compared to the prior year. The quarter from April to September of 2024-25 has shown an increase of more than four times to $520 million, compared to $117 million in the corresponding period of the last fiscal year.
From April 2000 to September 2024, the total foreign equity investment in the drugs and pharmaceuticals sector amounts to $23.05 billion, representing 3.25 percent of the overall FDI inflow into the nation during this timeframe.
The second quarter that concluded in September 2024 showed nearly a tenfold increase in fund infusion compared to the corresponding period last year. The period from July to September 2024 increased nearly ten times to $284 million, in contrast to the $27 million reported in the same timeframe last year.
The fiscal year’s April to June quarter showed a growth of 162 percent, reaching $236 million, up from $90 million in the same quarter of the prior fiscal year.
Of the overall FDI equity inflow of $708.7 billion up to September 2024, the services sector comprised over 16.25 percent of the total FDI equity inflow in US Dollar terms, followed by computers and software & hardware (15.11%), trading (6.51%), telecommunications (5.64%), the automobile industry (5.25%), construction (infrastructure) activities (4.97%), construction development including townships, housing, built-up infrastructure, and construction development projects (3.78%), drugs and pharmaceuticals (3.25%), chemicals (excluding fertilizers) (3.23%), and non-conventional energy (2.82%) from April 2000 to September 2024.
, CDSCO.jpg)
